Celldex Therapeutics, Inc.

NASDAQ•CLDX

CEO: Mr. Anthony S. Marucci M.B.A.

Sector: Healthcare

Industry: Biotechnology

Listing Date: 1986-05-15

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases. The company's clinical development programs CDX-0159, a Phase II monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity. It has research collaboration and license agreements with Yale University. The company was incorporated in 1983 and is headquartered in Hampton, New Jersey.

Contact Information

Perryville III Building, Suite 220 53 Frontage Road, Hampton, NJ, 08827, United States

908-200-7500

www.celldex.com

Market Cap

$2.19B

P/E (TTM)

-8.4

18.1

Dividend Yield

52W High

$35.79

52W Low

$17.85

52W Range

84%

Rank55Top 80.0%

2.6

F-Score

Modified Piotroski Analysis

Based on 10-year fundamentals

Weak • 2.6 / 9 points

Scoring Range (0-9)

8-9: Excellent Value

6-7: Strong Fundamentals

4-5: Average Quality

0-3: Weak Performance

Data Period: 2016-2025

Financial Dashboard

Q4 2025 Data

Revenue

$75.00K+0.00%

4-Quarter Trend

EPS

-$1.23+0.00%

4-Quarter Trend

FCF

-$64.93M+0.00%

4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Barzolvolimab Phase 3 Enrollment Complete Phase 3 CSU studies enrollment finished February 2026; topline data expected Q4 2026. PN/AD Phase 2 enrollment also complete.

R&D Spending Increased 50% Research and development expenses reached $245.1M in 2025, up 50% from $163.6M in 2024, funding clinical advancement.

Net Loss Widened Significantly Net loss increased 64% to $258.8M in 2025 versus $157.9M in 2024, driven by higher R&D costs.

Cash Position Remains Adequate Total cash and securities stood at $518.6M on December 31, 2025, funding operations through 2027.

Risk Factors

Need Capital To Fund Operations Company has no product revenue and requires substantial financing to complete clinical trials and achieve regulatory approval.

Clinical Development Failure Risk Drug candidates face risk of clinical failure at any stage, potentially precluding commercial revenue generation despite significant investment.

Regulatory Approval Uncertainty FDA review process is lengthy and uncertain; approval delays or limitations could severely restrict market potential and profitability.

Reliance on Third-Party Manufacturers Dependence on single-source CDMOs for manufacturing exposes operations to supply chain delays, quality issues, and compliance risks.

Outlook

Advance Barzolvolimab Phase 3 Data Expect topline data from EMBARQ-CSU1/2 trials in Q4 2026; PN Phase 2 data expected Summer 2026.

CDX-622 Data Anticipated Q3 2026 Multiple ascending dose data for bispecific candidate CDX-622 anticipated in third quarter 2026, supporting further development.

Expect Continued Operating Losses Anticipate incurring operating losses in 2026 and beyond due to planned significant costs for drug candidate development.

Prepare For Future Capital Raising Company plans further capital raising activities including licensing, debt issuance, or equity offerings to meet long-term liquidity needs.

Peer Comparison

Revenue (TTM)

HRMY

$868.45M

+21.5%

RCUS

$247.00M

-4.3%

SYRE

$90.49M

+0.0%

Gross Margin (Latest Quarter)

CLDX

100.0%

+0.0pp

ABCL

100.0%

+588.5pp

NUVB

99.0%

+182.9pp

Key Metrics

Symbol	Market Cap	P/E (TTM)	ROE (TTM)	Debt to Assets
CELC	$5.87B	-36.0	-203.2%	41.9%
SYRE	$4.50B	-166.0	-29.4%	0.0%
EWTX	$3.32B	-19.0	-32.0%	0.7%

Long-Term Trends

Last 4 Quarters

Revenue

Net Income

Operating Cash Flow

4Q Revenue CAGR

-52.4%

Growth Under Pressure

4Q Net Income CAGR

N/M

Profitability Shift

Cash Flow Stability

Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026

EPS:-

Revenue:-

Financials

Earnings Calls

Reports

News

Income Statement

Balance Sheet

Cash Flow Statement

Ratios

% Chg.

Income Statement	LTM

No Data